Durvalumab granted FDA priority review for the treatment of patients with extensive-stage small cell lung cancer.

[LUNGevityKristin 92]

"AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for IMFINZI in combination with standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC). A Prescription Drug User Fee Act (PDUFA) date is set for the first quarter of 2020...."

Read the whole article here: https://www.astrazeneca-us.com/content/az-us/media/press-releases/2019/imfinzi-durvalumab-granted-fda-priority-review-for-the-treatment-of-patients-with-extensive-stage-small-cell-lung-cancer-12022019.html